Allogeneic Cell Therapy Products

ANMD-MRS9-090 · Advanced Therapeutics & Biomanufacturing

A Global Sustainability Due Diligence & Market Research Study

History 2020–2024 · Base Year 2025 · Forecast 2025–2032 · Outlooks 2035 / 2040 / 2050 · Currency US$

WHY THIS REPORT

Allogeneic cell therapy products are the off-the-shelf future of cell medicine — the donor-derived and iPSC-derived CAR-T, NK-cell, MSC and gamma-delta T-cell therapies designed to be manufactured at scale and dosed on demand, rather than built per patient. This decision-grade study sizes the global market three ways — value, patients treated and dose volume — across product type, cell source and application, across seven regions and four scenarios to 2032, with outlooks to 2050.

SUSTAINABILITY & SDG IMPACT — THE ANMD LENS

Sustainability is this report's backbone, not an afterthought. Allogeneic platforms' core contribution is access and affordability — scalable, off-the-shelf cell therapy at lower cost — alongside the footprint of cell manufacturing.

Mapped Sustainable Development Goals:

SDG 3	SDG 9	SDG 10	SDG 12	SDG 17
Good Health & Well-Being	Industry, Innovation & Infrastructure	Reduced Inequalities	Responsible Consumption	Partnerships for the Goals

Measurable sustainability outcomes assessed:

- Scalable, off-the-shelf access at lower cost
- Equitable patient access and affordability
- Manufacturing energy and single-use waste
- Cold-chain logistics and pricing as material risks

Framework alignment: Double materiality mapped to GRI, SASB, ISSB, TCFD, TNFD, CSRD and the EU Taxonomy, with greenwashing and SDG-washing screens applied throughout.

WHAT'S INSIDE AT A GLANCE

53 Chapters	**9** Report Parts	**7** Regions Covered	**40+** Country Markets
2025–32 Forecast Horizon	**4** Forward Scenarios	**20+** Companies Profiled	**5** SDGs Mapped

REPORT COVERAGE

Geographic scope: North America, Europe, Asia Pacific, Latin America, Africa, Middle East and Rest of World — with named country intelligence. North America leads the pipeline; Europe holds gene-editing strength; Asia Pacific is building capability; other regions assessed on their own merits.

MARKET OVERVIEW

From per-patient manufacturing to off-the-shelf supply — where cell therapy targets scale, speed and access.

Allogeneic cell therapy is an emerging, high-potential field. Demand is driven by the promise of off-the-shelf availability, lower cost-of-goods and scalable manufacturing — with persistence, immune rejection and gene editing central to viability. The market is read three ways — value, patients treated and dose volume — and forecast under four scenarios, each region reported separately.

- **North America leads the pipeline** — United States, across CAR-T, NK and iPSC platforms
- **Europe holds gene-editing strength** — Switzerland and France, enabling allogeneic engineering
- **Asia Pacific is building capability** — Japan and China, advancing allogeneic and iPSC programmes
- **Off-the-shelf manufacturing is the differentiator** — donor and iPSC sourcing decouple supply from the patient, targeting scale and cost

REGIONAL OUTLOOK

Across seven reporting regions, the report separates leading markets from high-growth and emerging ones — each profiled in full rather than aggregated into Rest of World.

Region	Stage	Lead Markets & Drivers
North America	Pipeline leader	United States — CAR-T, NK & iPSC platforms
Europe	Gene-editing strength	Switzerland, France — allogeneic engineering
Asia Pacific	Building capability	Japan, China — regional iPSC programmes
Latin America	Frontier	Brazil — trial access
Africa	Frontier	South Africa — research access
Middle East	Emerging	Israel, UAE — research & investment

KEY MARKET DRIVERS & RESTRAINTS

Drivers	Restraints
• Off-the-shelf availability & speed	• Persistence & durability vs autologous
• Lower cost-of-goods vs autologous	• Immune rejection & host-versus-graft
• Scalable iPSC & donor manufacturing	• Manufacturing & differentiation complexity
• Gene-editing-enabled engineering	• Early clinical maturity & TRL
• Expansion across cell types (NK, MSC)	• Regulatory & reimbursement uncertainty

SEGMENTATION SNAPSHOT

By Product Type	Allogeneic CAR-T · NK-cell · iPSC-derived · MSC / stromal-cell · gamma-delta T-cell
By Cell Source	Donor-derived · iPSC-derived · cord / tissue-derived
By Application	Oncology · rare / genetic disease · immunology & infectious disease
By End User	Hospitals · pharma / biotech · CDMOs · academia
By Stage	Clinical · preclinical
By Business Model	Product sales · CDMO services · licensing

TABLE OF CONTENTS — PARTS & CHAPTERS

The full report is organised into nine parts across 53 chapters, listed below. Detailed sub-headings, country tables and directories are provided in the full report.

Part V — Company, Competition, Patent and Project Intelligence

Part VI — Sustainability, ESG, SDG, Climate and Natural-Capital Intelligence

Part VII — Supply Chain, Policy, Legal, Economics and Finance

Part VIII — Scenario, Future Intelligence and Final Due Diligence Verdict

Part IX — Annexes, Directories and Reference Material

COMPETITIVE & INVESTMENT SNAPSHOT

The competitive field spans allogeneic pioneers, iPSC platforms and gene-editing enablers. Deal activity — gene-editing partnerships, iPSC-platform deals and CDMO build-out — signals a field racing toward scalable, off-the-shelf cell therapy.

Representative players profiled in the full report:

Allogene Therapeutics, Inc. · Fate Therapeutics, Inc. · Gilead Sciences, Inc. · Century Therapeutics, Inc. · CRISPR Therapeutics AG · Cellectis S.A. · Sana Biotechnology, Inc. · and further profiled players across pioneers and gene-editing enablers.

Investment intelligence: venture, infrastructure, development, climate and blended finance, green bonds and sustainability-linked loans — culminating in a bankability assessment and a conditional investment view.

KEY QUESTIONS THIS REPORT ANSWERS

- How large is the global allogeneic cell therapy market, and how fast will it grow to 2032?
- Which regions, countries and segments offer the strongest risk-adjusted opportunity?
- How does off-the-shelf manufacturing change value versus autologous therapy?
- Who leads, and where is the competitive and patent white space?
- Is the investment case bankable — and under what conditions?
- How does the category align with the SDGs, equitable access and manufacturing-footprint expectations?

WHY ANMD — THE DIFFERENCE

Most market studies stop at units and revenue. This report is built as a sustainability due diligence instrument — fusing market sizing with ESG, SDG, climate, water and natural-capital intelligence and a decision-ready bankability view in a single architecture.

- **Triangulated sizing** — every market read three ways so value, volume and the physical-unit views reconcile rather than conflict.
- **Region-honest forecasting** — Latin America, Africa and the Middle East reported in full, never hidden inside Rest of World, every forecast resolved to the 2025 base year.
- **Integrated evidence base** — company, patent and project databases linked to the analysis, with published-filing patents and FTO treated as an indicator, not a legal conclusion.
- **No-fabrication discipline** — every estimate carries a data-confidence rating and disclosed sources; gaps are flagged for further diligence, never filled with invented numbers.
- **Anti-greenwashing rigour** — SDG-washing and greenwashing screens plus claim-substantiation checks built into the ESG and project analysis.
- **Decision-first structure** — 9 Parts and 53 Chapters culminating in stakeholder playbooks and a clear, conditional investment view.

WHO SHOULD BUY THIS REPORT

Investors, biopharma, CDMOs, hospitals, payers, regulators, lenders and policymakers, and strategic corporate planners and decision-makers.

Access the Full Report

The complete report delivers all 53 chapters in full, with every sub-heading, country table, company and patent directory, forecast model and due diligence checklist.

Purchase at **www.anewmarketdynamics.com** · Standard & Premium licences · Single-Site (SSL) and Global-Site (GSL) options at checkout.

Want the Complete Detailed Table of Contents?

This prospectus lists the nine parts and 53 chapters. The complete detailed table of contents — every sub-heading, country table, exhibit, company and patent directory and annex — is available on request to registered users. To receive it, register with your official company email at **www.anewmarketdynamics.com**. The full detailed table of contents will be sent directly to your registered company email address.